Cencora, Inc. Forecasted to Earn FY2024 Earnings of $13.67 Per Share (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Cencora in a research report issued to clients and investors on Thursday, September 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $13.67 per share for the year, up from their previous forecast of $13.63. The consensus estimate for Cencora’s current full-year earnings is $13.61 per share. Leerink Partnrs also issued estimates for Cencora’s Q3 2025 earnings at $3.68 EPS.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the prior year, the business posted $2.92 EPS. Cencora’s quarterly revenue was up 10.8% on a year-over-year basis.

Several other brokerages have also commented on COR. JPMorgan Chase & Co. increased their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Leerink Partners reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Robert W. Baird upped their price objective on shares of Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average price target of $258.63.

Cencora Stock Performance

Shares of COR opened at $236.29 on Friday. The company’s fifty day moving average is $232.08 and its 200-day moving average is $233.16. Cencora has a 12 month low of $171.65 and a 12 month high of $247.66. The firm has a market cap of $47.13 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 1.57 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.

Institutional Investors Weigh In On Cencora

Hedge funds have recently made changes to their positions in the company. Rise Advisors LLC acquired a new stake in shares of Cencora during the 1st quarter worth about $25,000. Legacy Bridge LLC acquired a new stake in shares of Cencora during the 1st quarter worth about $27,000. New Millennium Group LLC acquired a new stake in shares of Cencora during the 2nd quarter worth about $26,000. TCTC Holdings LLC bought a new position in shares of Cencora in the 1st quarter valued at about $29,000. Finally, TFO Wealth Partners LLC bought a new position in shares of Cencora in the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The disclosure for this sale can be found here. Insiders sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 in the last ninety days. Company insiders own 15.80% of the company’s stock.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.